Publications by authors named "D Sangiolo"
Background: Colorectal cancer (CRC) is the third most common cancer worldwide, with highly variable prognosis and response to treatment. A large subset of patients does not respond to standard treatments or develops resistance. As an alternative, adoptive immunotherapy based on chimeric antigen receptor (CAR)-transduced immune cells has been proposed, however with significant adverse events.
View Article and Find Full Text PDFArticle Synopsis
- Intraperitoneal cellular immunotherapy using CAR-redirected lymphocytes shows promise for tackling peritoneal carcinomatosis from ovarian cancer, currently under clinical trial evaluation.
- Researchers developed 3D experimental models that mimic the unique environment of peritoneal carcinomatosis, demonstrating that MSLN-CAR.CIK lymphocytes effectively kill ovarian cancer cells both in liquid and solid tumor contexts.
- The study revealed that fluid flow enhances tumor localization and killing in floating structures, while CAR-CIK cells are capable of penetrating and targeting solid tumor aggregates, providing insights for future locoregional cell therapy strategies in affected patients.
Purpose: The IMMUNOSARC trial combined an antiangiogenic agent (sunitinib) with a PD1 inhibitor (nivolumab) in advanced sarcomas. Here, we present the first correlative studies of the soft-tissue sarcoma cohort enrolled in this trial.
Experimental Design: Formalin-fixed paraffin-embedded and peripheral blood samples were collected at baseline and week 13.
HER2 amplification occurs in approximately 5% of colorectal cancer (CRC) cases and is associated only partially with clinical response to combined human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR)-targeted treatment. An alternative approach based on adoptive cell therapy using T cells engineered with anti-HER2 chimeric antigen receptor (CAR) proved to be toxic due to on-target/off-tumor activity. Here we describe a combinatorial strategy to safely target HER2 amplification and carcinoembryonic antigen (CEA) expression in CRC using a synNotch-CAR-based artificial regulatory network.
View Article and Find Full Text PDFThe MET receptor is one of the main drivers of 'invasive growth', a multifaceted biological response essential during embryonic development and tissue repair that is usurped by cancer cells to induce and sustain the malignant phenotype. MET stands out as one of the most important oncogenes activated in cancer and its inhibition has been explored since the initial era of cancer-targeted therapy. Different approaches have been developed to hamper MET signaling and/or reduce MET (over)expression as a hallmark of transformation.
View Article and Find Full Text PDF